Mercaptopurine versus placebo to prevent recurrence of Crohn's disease after surgical resection (TOPPIC): a multicentre, double-blind, randomised controlled trial.
- Mowat, C.
- Arnott, I.
- Cahill, A.
- Smith, M.
- Ahmad, Tariq
- Subramanian, S.
- Travis, S.
- Morris, J.
- Hamlin, J.
- Dhar, A.
- Nwokolo, C.
- Edwards, C.
- Creed, T.
- Bloom, S.
- Yousif, M.
- Thomas, L.
- Campbell, S.
- Lewis, S. J.
- Sebastian, S.
- Sen, S.
- Lal, S.
- Hawkey, C.
- Murray, C.
- Cummings, F.
- Goh, J.
- Lindsay, J. O.
- Arebi, N.
- Potts, L.
- McKinley, A. J.
- Thomson, J. M.
- Todd, J. A.
- Collie, M.
- Dunlop, M. G.
- Mowat, A.
- Gaya, D. R.
- Winter, J.
- Naismith, G. D.
- Ennis, H.
- Keerie, C.
- Lewis, S. C.
- Prescott, R. J.
- Kennedy, Nicholas A.
- Satsangi, J.
Publication date
December 2016
DOI Publisher
Elsevier BV Journal
The Lancet Gastroenterology & HepatologyAbstract
EDGE Project ID: 2508Up to 60% of patients with Crohn's disease need intestinal resection within the first 10 years of diagnosis, and postoperative recurrence is common. We investigated whether mercaptopurine can prevent or delay postoperative clinical recurrence of Crohn's disease.This article is freely available via Open Access. Click on the Additional Link above to access the full-text via the publisher's site.Medical Research Council (07/MRE00/74
Add to ORKG